CINCINNATI, OH--(Marketwire - Jul 18, 2012) - Medpace, Inc. today announced the addition of Manuela Niewel, MD, PhD, as a Sr. Medical Director in the area of Oncology. Dr. Niewel is a senior-level medical oncologist, with over 20 years of clinical research experience at prominent clinical research companies specializing in studies for oncologic indications.
Dr. Niewel was most recently a Sr. Medical Director Oncology with PharmaNet in Germany. In addition, she has led research teams for both pharmaceutical and clinical research organizations at companies such as Nycomed Amersham, Synthelabo Recherche, and Cyanamid. She will be charged with supporting Medpace European growth with regard to oncology studies supporting global Medpace sponsors.
"Medpace conducts a great majority of oncology studies in Europe. Having a medical oncologist of Dr. Niewel's stature to support Medpace studies is a key advantage," said Dr. Ursula Schlichtiger, Medpace Vice-President, Medical & Regulatory Affairs. "Dr. Niewel will support our oncology studies, bringing therapeutic and scientific depth to the project teams across Europe."
Dr. Niewel received her medical degree and Oncology specialist training from the University of Munich (TU) and is fluent in German, French, and English. She has been involved in the management and conduct of oncology-specific and other therapeutic clinical trial programs throughout her career.
Dr. Niewel will be based in Munich, Germany and support Medpace global teams conducting oncology studies.
Medpace is a leading global full-service clinical research organization providing Phase I-IV core development services for drug, biologic, and device programs. With medical and regulatory expertise in multiple therapeutic specialties, Medpace has assembled the industry's most experienced and therapeutically focused teams to execute at every level of the company's operations, providing complete and seamless drug development services.
Medpace creates strategic partnerships with pharmaceutical and biotechnology companies to provide the most efficient and cost-effective path to drug development -- from program planning and execution to product approval.
With more than 1000 employees and clinical trial experience in over 40 countries, Medpace has the global reach and capability to conduct studies and navigate regulatory requirements worldwide. In addition to Phase II-IV development services, Medpace provides Phase I / IIA clinical services from Medpace Clinical Pharmacology, central laboratory and therapeutically specialized testing from Medpace Reference Laboratories, complete bioanalytical services in all stages of drug development from Medpace Bioanalytical Laboratories, centralized imaging core laboratory management and reading from Imagepace, and medical device development from Medpace Medical Device.
Visit the Medpace website at www.medpace.com